Armata Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ARMP | AVIR | INVA | ACXP | AVCT.L | ABUS | |
|---|---|---|---|---|---|---|
| Market cap | 116.75M | 357.71M | 1.54B | 5.64M | 247.70M | 622.30M |
| P/E (TTM) | — | — | 5.0 | — | — | 5.1 |
| Forward P/E | -1.5 | -3.0 | 9.6 | -0.6 | -21.0 | -24.6 |
| Price/book | -0.5 | 1.8 | 1.4 | 0.6 | 70.7 | 3.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −45.41% | +37.23% | +14.81% | −80.19% | −20.03% | −15.84% |
| Today | +1.62% | +6.95% | +1.58% | +0.98% | −1.57% | +4.64% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ARMP news ›Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
Oct 07, 2026, 07:00 ET Issued patents provide intellectual property protection for clinical candidates, AP-SA02 and AP-PA02, until at least 2041 Armata's bacteriophage intellectual property portfolio includes 15 patent families with issued…
Armata Pharmaceuticals secures patents for key bacteriophage therapies through 2041, advancing antibiotic-resistant infection treatments.
Armata Pharmaceuticals announced the issuance of two U.S. patents protecting its bacteriophage therapy candidates AP-SA02 and AP-PA02 until at least 2041. These patents strengthen Armata's intellectual property in developing treatments for…
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
/PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the... Fulfills important regulatory milestone for AP-SA02 on the path toward a future…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- pluang.com1
- prnewswire.com1
- stocktitan.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.